Download PDF
Thromb Haemost 2010; 103(06): 1152-1160
DOI: 10.1160/TH09-11-0759
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study

Benilde Cosmi
1   Department of Angiology & Blood Coagulation “Marino Golinelli”, S. Orsola-Malpighi University Hospital, Bologna, Italy
,
Cristina Legnani
1   Department of Angiology & Blood Coagulation “Marino Golinelli”, S. Orsola-Malpighi University Hospital, Bologna, Italy
,
Alberto Tosetto
2   Department of Hematology, S. Bortolo Hospital, Vicenza, Italy
,
Vittorio Pengo
3   Department of Clinical and Experimental Medicine, Division of Clinical Cardiology, University Hospital, Padua, Italy
,
Angelo Ghirarduzzi
4   Department of Internal Medicine I, Angiology, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
,
Sophie Testa
5   Haemostasis & Thrombosis Center, General Hospital, Cremona, Italy
,
Domenico Prisco
6   Department of Medical and Surgical Critical Care, University of Florence and Centro Trombosi, A.O. U. Careggi , Firenze, Italy
,
Daniela Poli
6   Department of Medical and Surgical Critical Care, University of Florence and Centro Trombosi, A.O. U. Careggi , Firenze, Italy
,
Armando Tripodi
7   Angelo Bianchi Bonomi Hemophilia & Thrombosis Center, Department of Internal Medicine, University & IRCCS Maggiore Hospital, Milan, Italy
,
Gualtiero Palareti
7   Angelo Bianchi Bonomi Hemophilia & Thrombosis Center, Department of Internal Medicine, University & IRCCS Maggiore Hospital, Milan, Italy
,
for the PROLONG Investigators › Author Affiliations Financial support: The study was supported by the Italian Federation of Anticoagulation Clinics (FCSA) and by the Dept. of Angiology & Blood Coagulation of the University Hospital S. Orsola-Malpighi of Bologna (Coordinating Center), Italy. The Instrumentation Laboratory company (Milan) provided the kits for D-dimer measurement (Clearview Simplify-D dimer test).
Further Information

Publication History

Received: 06 November 2009

Accepted after major revision: 12 January 2010

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

Summary

The PROLONG randomised clinical trial showed that an abnormal D-dimer at one month after vitamin K antagonist (VKA) suspension for a first episode of unprovoked venous thromboembolism (VTE) is associated with a higher risk of recurrence. However, other patient characteristics, such as comorbidities, in combination with D-dimer could also influence the recurrence risk. It was the objective of this study to assess the predictive value of comorbidities and D-dimer in combination for recurrence after withdrawal of VKA in patients enrolled in the PROLONG study. On the day of VKA suspension, the presence of known (coronary, peripheral,cerebral) vascular disease, chronic inflammatory bowel disease, chronic obstructive pulmonary disease, autoimmune disease, diabetes, arterial hypertension, obesity and dyslipidaemias was registered. D-dimer was measured at 30 ± 10 days afterwards. The primary outcome was recurrent objectively documented VTE. Mean follow-up was 2.55 years. An abnormal D-dimer was observed in 44% (135/309) of patients with comorbidities and in 29% (87/299) of patients without (p=0.0003). An on-treatment analysis was conducted in 483 patients in whom VKAs were not resumed. In patients with a normal D-dimer, recurrences were observed in 14.3% (24/168) of patients with comorbidities and 10.8% (22/203) of subjects without (p=ns). In patients with an abnormal D-dimer, recurrences were observed in 24.6% (16/65) patients with comorbidities and 21.3% (10/47) of patients without (p=ns). Although abnormal D-dimer levels were significantly more frequent in patients with comorbidities, D-dimer was an independent risk factor for recurrence and the presence of comorbidities did not increase the risk of recurrence associated with an abnormal post-anticoagulation D-dimer.

ClinicalTrials.gov number: NCT00264277

Keywords

Venous thromboembolism - risk factors - hypercoagulability - oral anticoagulants - atherosclerosis

* The PROLONG investigators are listed in the Acknowledgements.


 

  • References

  • 1 Schulman S, Rhedin AS, Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-1665.
    CrossrefPubMedGoogle Scholar
  • 2 Kearon C, Gent M, Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907.
    CrossrefPubMedGoogle Scholar
  • 3 Agnelli G, Prandoni P, Santamaria MG. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345: 165-169.
    CrossrefPubMedGoogle Scholar
  • 4 Kearon C, Kahn S R, Agnelli G. et al. Antithrombotic Therapy for Venous Thromboembolic Disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 2008; 133: 454S-545S.
    PubMedGoogle Scholar
  • 5 Heit JA, Mohr DN, Silverstein MD. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism – A population-based cohort study. Arch Intern Med 2000; 160: 761-768.
    CrossrefPubMedGoogle Scholar
  • 6 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception- cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
    CrossrefPubMedGoogle Scholar
  • 7 Kearon C, Ginsberg JS, Kovacs MJ. et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
    CrossrefPubMedGoogle Scholar
  • 8 Palareti G, Legnani C, Cosmi B. et al. Risk of venous thromboembolism recurrence: High negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87: 7-12.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Palareti G, Legnani C, Cosmi B. et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313-318.
    CrossrefPubMedGoogle Scholar
  • 10 Eichinger S, Minar E, Bialonczyk C. et al. D-dimer levels and risk of recurrent venous thromboembolism. J Am Med Assoc 2003; 290: 1071-1074.
    CrossrefPubMedGoogle Scholar
  • 11 Palareti G, Cosmi B, Legnani C. et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780–1789. Erratum in: N Engl J Med 2006; 355: 2797.
    PubMedGoogle Scholar
  • 12 Cosmi B, Legnani C, Tosetto A. et al. Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. J Thromb Thrombolysis 2009; 28: 381-388.
    CrossrefPubMedGoogle Scholar
  • 13 Becattini C, Agnelli G, Prandoni P. et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005; 26: 77-83.
    CrossrefPubMedGoogle Scholar
  • 14 Tsai AW, Cushman M, Rosamond WD. et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182-1189.
    CrossrefPubMedGoogle Scholar
  • 15 Prandoni P, Ghirarduzzi A, Prins MH. et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006; 04: 1891-1896.
    CrossrefPubMedGoogle Scholar
  • 16 Luxembourg B, Schmitt J, Humpich M. et al. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP). Thromb Haemost 2009; 102: 668-675.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 2010; 103: 56-61.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Folsom AR, Lutsey PL, Astor BC. et al. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 2009; 102: 615-619.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Matta F, Singala R, Yaekoub AY. et al. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009; 101: 134-138.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Prandoni P, Cogo A, Bernardi E. et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation 1993; 88: 1730-1735.
    CrossrefPubMedGoogle Scholar
  • 21 Cini M, Legnani C, Cavallaroni K. et al. A new rapid bedside assay for D-dimer measurement (Simplify D-dimer) in the diagnostic work-up for deep vein thrombosis. J Thromb Haemost 2003; 01: 2681-2683.
    CrossrefPubMedGoogle Scholar
  • 22 Wisloff F, Jacobsen EM, Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2002; 108: 263-271.
    CrossrefPubMedGoogle Scholar
  • 23 Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002; 126: 1326-1336.
    PubMedGoogle Scholar
  • 24 Bertina RM, Koeleman BPC, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
    CrossrefPubMedGoogle Scholar
  • 25 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3‘-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
    PubMedGoogle Scholar
  • 26 Fedullo PF, Tapson VF. The evaluation of suspected pulmonary embolism. N Engl J Med 2003; 349: 1247-1256.
    CrossrefPubMedGoogle Scholar
  • 27 Kearon C. Diagnosis of pulmonary embolism. Can Med Assoc J 2003; 168: 183-194.
    PubMedGoogle Scholar
  • 28 Prandoni P, Noventa F, Ghirarduzzi A. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199-205.
    CrossrefPubMedGoogle Scholar
  • 29 Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415-3420.
    CrossrefPubMedGoogle Scholar
  • 30 Ay C, Tengler T, Vormittag R. et al. Venous thromboembolism – a manifestation of the metabolic syndrome. Haematologica 2007; 92: 374-380.
    CrossrefPubMedGoogle Scholar
  • 31 Lacut K, Oger E, Le Gal G. et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol 2004; 18: 477-482.
    CrossrefPubMedGoogle Scholar
  • 32 Doggen CJ, Lemaitre RN, Smith NL. et al. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2004; 02: 700-701.
    CrossrefPubMedGoogle Scholar
  • 33 Yang CC, Jick SS, Jick H. Statins and the risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 2002; 53: 101-105.
    CrossrefPubMedGoogle Scholar
  • 34 Kaba NK, Francis CW, Moss AJ. et al. Effects of lipids and lipid-lowerinf therapy on haemostatic factors in patients with myocardial infarction. J Thromb Haemost 2004; 02: 718-725.
    CrossrefPubMedGoogle Scholar
  • 35 Van de Ree MA, De Maat MPM, Kluft C. et al. Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. J Thromb Haemost 2003; 01: 1753-1757.
    CrossrefPubMedGoogle Scholar
  • 36 Legnani C, Palareti G, Cosmi B. et al. Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. Haematologica 2008; 93: 900-907.
    CrossrefPubMedGoogle Scholar